Get started
Author

Chinyere E. Okpara

Observed names: C. E. Okpara, C.E. Okpara, C.J. Okpara, Chinyere E Okpara, Chinyere Okpara
Observed institutions: University of Liverpool, NYU Langone Health, Eisai (Germany), Eisai (United Kingdom), Eisai (United States), NYU Grossman Long Island School of Medicine, Eisai (Japan), New York University
ORCID: 0000-0002-5621-9138
Observed ORCID: 0000-0002-5621-9138
OpenAlex ID: A5014514185
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 204
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
2021 · Chung-Han Lee, Amishi Yogesh Shah, et al. · The Lancet Oncology · 195
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
2023 · Vicky Makker, Nicoletta Colombo, et al. · Journal of Clinical Oncology · 173
PDF
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
2021 · Nathalie Gaspar, Rajkumar Venkatramani, et al. · The Lancet Oncology · 91
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 77
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
2022 · Robert J. Motzer, Matthew H. Taylor, et al. · Expert Review of Anticancer Therapy · 71
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆
2021 · N. Gaspar, Q. Campbell-Hewson, et al. · ESMO Open · 63
PDF
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
2023 · James Chih-Hsin Yang, Baohui Han, et al. · Journal of Thoracic Oncology · 61
PDF
Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei
2020 · Ali H Alghamdi, Jane C Munday, et al. · eLife · 48
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
2023 · Viktor Grünwald, Thomas Powles, et al. · Frontiers in Oncology · 44
PDF
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
2023 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 44
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
2025 · Natasha B. Leighl, Luis Paz-Ares, et al. · Journal of Thoracic Oncology · 28
PDF
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
2024 · Nathalie Gaspar, Giun-Yi Hung, et al. · JAMA Oncology · 27
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
2024 · Antonio González-Martín, Hyun Cheol Chung, et al. · Gynecologic Oncology · 27
PDF
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
2023 · Nobuaki Matsubara, Ronald de Wit, et al. · European Urology · 27
PDF
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
2024 · R.J. Motzer, C. Porta, et al. · Annals of Oncology · 26
PDF
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
2024 · Viktor Grünwald, Rana R. McKay, et al. · International Journal of Cancer · 22
PDF
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas
2022 · Andrew DJ. Pearson, Nathalie Gaspar, et al. · European Journal of Cancer · 22
PDF
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
2021 · J.C-H. Yang, A. Luft, et al. · Annals of Oncology · 20
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
2023 · Nicoletta Colombo, Domenica Lorusso, et al. · The Oncologist · 16
PDF
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
2024 · Hyun Cheol Chung, Esma Saada‐Bouzid, et al. · Cancer · 15
PDF
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
2025 · Roy S. Herbst, Byoung Chul Cho, et al. · Journal of Thoracic Oncology · 14
PDF
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
2025 · A. Arance, M.-A. Berciano-Guerrero, et al. · Annals of Oncology · 11
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
2024 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 10
65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy
2023 · N. Leighl, L. Paz-Ares, et al. · Immuno-Oncology Technology · 10
PDF
Works count: 105
Citation count: 1,462
H-index: 19
I10-index: 25
Year
Topic
Type